Study On the Expression Level and Clinical Significance of VISTA in Patients With Vascular Cognitive Impairment

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-80
SponsorFirst Affiliated Hospital of Harbin Medical University

About this trial

1\. Explore the expression level of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients with cardiovascular risk factors; 2. Discuss the correlation between different risk factors (mainly hypertension, diabetes, smoking, hyperlipidemia, hyperhomocysteinemia, etc.) and the expression level of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients with cerebrovascular diseases and immune-inflammatory related diseases of the nervous system; 3. Explore the correlation between different immune inflammatory factors (IL1, IL6, IL10, INFγ, TNFα) and the expression level of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients; 4. Track and explore the dynamic changes of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients with cardiovascular risk factors in 3 months, 1 year, 3 years, and 5 years.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

The study included 100 subjects, including 50 patients with VCI and 50 normal controls. The diagnosis of VCI was based on the diagnostic criteria for psychiatric disorders in the fifth revised edition of the "Diagnostic and Statistical Manual of Mental Disorders" of the American Psychiatric Association;

All relevant examination and cognitive testing work in this study obtained informed consent from the subjects and their families.

Disqualifiers

None

Trial population

We retrospectively enrolled consecutive patients with cardiovascular risk factors from the First Affiliated Hospital of Harbin Medical University.

Trial design

Design model

Case-control

Time perspective

Retrospective

Treatments tested in this trial

  • Neuropsychological testing

    Diagnostic test

    The primary outcomes were Mini-Mental State Examination and Montreal Cognitive Assessment scores for screening of cognitive decline, which are recommended by NINDS-AIREN. The secondary outcomes included the performance in five cognition domains: (1) verbal memory, Hopkins Verbal Learning Test ; (2) visual-spatial ability, Clock Drawing test; (3) executive function, Trail Making test (TMT) (B time); (4) attention, TMT (A time); and (5) language tests, Boston Naming test2 (BNT-2)

Treatment groups

400 Participants
are divided into 2 treatment groups
Group A: Control1 intervention
Group B: Case1 intervention

Trial outcomes

Primary outcomes

1

Patient characteristics

Time frame
2023.03.01-2028.11.30
2

VISTA expression in PBMCs in the VCI and control groups

Time frame
2023.03.01-2028.11.30

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.